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abstract
PURPOSE SORCE is an international, randomized, double-blind, three-arm trial of sorafenib after surgical
excision of primary renal cell carcinoma (RCC) found to be at intermediate or high risk of recurrence.
PATIENTS AND METHODS We randomly assigned participants (2:3:3) to 3 years of placebo (arm A), 1 year of
sorafenib followed by 2 years of placebo (arm B), or 3 years of sorafenib (arm C). The initial sorafenib dose was
400 mg twice per day orally, amended to 400 mg daily. The primary outcome analysis, which was revised as
a result of external results, was investigator-reported disease-free survival (DFS) comparing 3 years of sorafenib
versus placebo.
RESULTS Between July 2007 and April 2013, we randomly assigned 1,711 participants (430, 642, and 639
participants in arms A, B, and C, respectively). Median age was 58 years, 71% of patients were men, 84% had
clear cell histology, 53% were at intermediate risk of recurrence, and 47% were at high risk of recurrence. We
observed no differences in DFS or overall survival in all randomly assigned patients, patients with high risk of
recurrence, or patients with clear cell RCC only. Median DFS was not reached for 3 years of sorafenib or for
placebo (hazard ratio, 1.01; 95% CI, 0.83 to 1.23; P 5 .95). We observed nonproportional hazards; the re-
stricted mean survival time (RMST) was 6.81 years for 3 years of sorafenib and 6.82 years for placebo (RMST
difference, 0.01 year; 95% CI,20.49 to 0.48 year; P5 .99). Despite offering treatment adaptations, more than
half of participants stopped treatment by 12 months. Grade 3 hand-foot skin reaction was reported in 24% of
participants on sorafenib.
CONCLUSION Sorafenib should not be used as adjuvant therapy for RCC. Active surveillance remains the
standard of care for patients at intermediate or high risk of recurrence after nephrectomy and is the appropriate
control of our current international adjuvant RCC trial, RAMPART.
J Clin Oncol 38:4064-4075. © 2020 by American Society of Clinical Oncology
INTRODUCTION
In 2018, . 400,000 new renal cell carcinomas (RCCs)
were diagnosed, and 175,098 deaths were attributed to
RCC worldwide.1 Two thirds of patients with RCC present
with disease confined to the kidney, which is potentially
curable by surgery alone. Scoring systems, such as the
Leibovich score, use clinical factors to categorize patients
according to their risk of relapse or death. Patients with
intermediate- or high-risk RCC after surgical resection are
at significant risk of relapse and death. The 5-year re-
lapse rate for these patients is 30%-40%; 5-year survival
has been reported at 74.8%, which declines steeply to
16% once patients develop metastatic disease.2
Effective treatments to reduce the risk of recurrence or
cancer death in patients with locoregional RCC remain
an unmet clinical need. Adjuvant strategies in RCC,
including cytokines, radiotherapy, and hormone ther-
apy, have been explored with no success.3 Oral tyrosine
kinase inhibitors (TKIs) targeting the vascular endothelial
growth factor (VEGF) receptor, including sunitinib,
sorafenib, and pazopanib, are effective in metastatic
RCC, which supported their evaluation in the adjuvant
setting and our decision to investigate the use of the
multitargeted TKI sorafenib in the SORCE trial.4-6
Four randomized controlled trials investigating TKIs in
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S-TRAC (ClinicalTrials.gov identifier: NCT00375674), AS-
SURE (ClinicalTrials.gov identifier: NCT00326898), and
PROTECT (ClinicalTrials.gov identifier: NCT01235962)
explored 1 year of adjuvant TKI therapy, whereas ATLAS
(ClinicalTrials.gov identifier: NCT01599754) explored up to
3 years of TKI therapy.7-10 In S-TRAC, a modest disease-
free survival (DFS) benefit with 1 year of sunitinib was
observed based on blinded independent central review
(hazard ratio [HR], 0.76; 95%CI, 0.59 to 0.98; P5 .03).10,11
On the basis of these results, the US Food and Drug Ad-
ministration approved sunitinib for the adjuvant treatment
of patients with RCC at high risk of recurrence. The Eu-
ropean Medicines Agency did not approve sunitinib use in
this setting. Therefore, these results have not been uni-
versally practice changing, and the international standard
of care for resected RCC remains nephrectomy followed by
active surveillance.12,13
The particular value of SORCE is to settle the question of
adjuvant TKI therapy. Here, we report findings from the
primary analysis of SORCE, comparing participants who
were randomly assigned to receive 3 years of sorafenib with
those who were randomly assigned to receive placebo. We
also report the findings of our analyses of participants




SORCE (ClinicalTrials.gov identifier: NCT00492258) is an
international, double-blind, three-arm, randomized, phase
III trial evaluating different durations of adjuvant sorafenib
compared with placebo.
Participants
Eligible participants had histologically proven, completely
resected, clear cell or non–clear cell RCC at intermediate
(score, 3-5) or high risk (score, 6-11) of relapse as per the
Leibovich risk model.14 The Leibovich score is a validated
scoring model incorporating TNM stage, tumor size, nu-
clear grade, and presence of tumor necrosis. Details on the
features and calculation of the Leibovich score can be
found in Appendix Table A1 (online only). Patients with
resected metastatic (M1) disease were not eligible.
Participants were enrolled within 13 weeks of nephrectomy,
were $ 18 years old, had WHO performance status of 0 or
1, and demonstrated adequate bone marrow, renal, he-
patic, and pancreatic function. All participants provided
written informed consent.
Randomization and Masking
Participants were randomly assigned (2:3:3) using stratified
blocks to receive 3 years of placebo (arm A), 1 year of
sorafenib followed by 2 years of placebo (arm B), or 3 years
of sorafenib (arm C). SORCE was a double-blind trial.
Participants were stratified by country and Leibovich
risk group.
Treatment and Follow-Up
The initial starting dose of sorafenib was 400mg twice daily,
with permitted dose reductions in the event of toxicity, first
to 400 mg once daily and then to 400 mg on alternate days.
In January 2009, we amended the starting dose to 400 mg
once daily to address a higher than expected discontinu-
ation rate (protocol version 1.4, November 2008). After
3 weeks of treatment, the dose could be maintained or
escalated to the full dose of 400 mg twice daily at clinician
discretion. Pill counts were performed at assessment visits
to allow assessment of dosing compliance.
Patients were assessed at weeks 3 and 6 after the start of
their treatment to identify and treat any early toxicities and
every 3 months for adverse events (AEs). Imaging alter-
nated between chest x-ray and contrast computed to-
mography (CT) of the chest and abdomen every 3 months
CONTEXT
Key Objective
We designed SORCE to investigate the role of sorafenib in prolonging disease-free survival (DFS) and overall survival (OS) in
patients with resected renal cell cancer (RCC) found to be at immediate or high-risk of recurrence.
Knowledge Generated
We observed no benefit for DFS or OS after up to 3 years of sorafenib treatment. Moreover, grade $ 3 toxicities were
experienced by six in 10 patients who received treatment. A reduction in the initial starting dose improved compliance,
but despite offering treatment adaptations, over half of participants stopped treatment by 12 months.
Relevance
SORCE results are definitive; sorafenib should not be used as adjuvant therapy for patients with resected RCC. SORCE is the
fifth and final trial to report on the role of tyrosine kinase inhibitor therapy as an adjuvant treatment of RCC. SORCE results
confirm that active surveillance remains the global standard of care for patients at intermediate or high risk of recurrence
after nephrectomy.
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during treatment. After completion of treatment, partici-
pants had chest x-rays only every 6 months until year 5 and
then annually until year 10. Recurrence was assessed by
local investigators.
Outcome Measures
The primary outcome measure is DFS, defined as the in-
terval from random assignment to first evidence of local
recurrence, distant metastases, or death from RCC. Sec-
ondary outcomes included overall survival (OS), defined as
the time from randomization to death from any cause;
metastasis-free survival (MFS), defined as the time from
randomization to first evidence of metastases or death from
RCC; RCC-specific survival time; and safety (using CTCAE
v3.0). Participants alive and without an event at the time of
each time-to-event analysis were censored on the date they
were last seen on the trial.
Changing the Primary Research Question
The original primary objective in SORCE was to determine
whether at least 1 year of treatment with sorafenib in-
creases DFS compared with placebo (a comparison of arms
B and C combined v arm A). Primary results from the
ASSURE and S-TRAC trials were reported after SORCE
closed to recruitment. Considering these results and
without knowledge of the developing outcome data, the
SORCE Trial Management Group (TMG) and the in-
dependent members of the executive oversight Trial
Steering Committee approved a change to the primary
analysis of SORCE. These changes are documented in our
protocol and statistical analysis plan and were all agreed on
before database lock.15
The revised primary analysis objectives were as follows:
Does up to 3 years of treatment with sorafenib increase DFS
compared with placebo (a comparison of arm C v arm A),
and if so, does up to 1 year of sorafenib (arm B) increase
DFS compared with placebo (arm A)? A closed testing
procedure was used for the second question, which nat-
urally preserves the type I error. If the analysis of the first
objective did not show statistical significance, results for the
second objective would still be presented for completeness,
although no statistical inferences can be drawn.
Study Oversight
The trial was approved by national regulatory and ethical
committees in each participating country and was con-
ducted in accordance to the principles of Good Clinical
Practice, the Declaration of Helsinki, and all applicable
regulatory requirements and laws. An Independent Data
Monitoring Committee (IDMC) reviewed participant safety
on a regular basis and efficacy data at prespecified time
points. An executive Trial Steering Committee received trial
reports on at least an annual basis.
Sample Size
The sample size for SORCE was based on the original
primary research question. It was calculated using the ART
software assuming an HR of 0.75 between arm A and arms
B and C combined.16 We assumed conservatively that the 2
additional years of sorafenib in arm C would not increase
DFS compared with arm B. DFS at 3 years for participants
in arm A, obtained from Leibovich et al14 and restricted to
the intermediate and poor prognostic groups, was esti-
mated to be 63.5%. To demonstrate a clinically important
improvement in 3-year DFS from 63.5% to 71% (HR, 0.75)
with sorafenib, using a log-rank test with 90% power and
5% two-sided significance level, required 608 DFS events,
179 of which would be in arm A. The total sample size target
was 1,656 participants (414 participants in arm A and 621
in each of arms B and C).
Because recruitment was complete at the time of changing
the primary research questions, the sample size was not
recalculated. The target number of control arm events
remained unchanged at 179 DFS events. With this number
of events in the control arm and with all other assumptions
unchanged, the study had 86% power to detect an HR of
0.75 at the 5% two-sided significance level. Two subgroup
analyses were prepowered before analysis (Appendix,
online only)—DFS in participants with a high-risk Leibovich
score (score, 6-11) and in participants with clear cell
histology.
Interim Assessment by the IDMC
Two planned interim efficacy analyses were performed after
approximately 200 and 400 of the planned events had
occurred using a stringent two-sided significance level of
P 5 .001 at each interim analysis (Peto boundary). The
IDMC requested one additional efficacy analysis, which
was carried out after approximately 500 events. On each
occasion, the IDMC recommended that the trial continue as
planned. The final analysis was performed with no ad-
justment for multiple testing.
Statistical Analysis Plan
A final statistical analysis plan was approved before any
analyses were performed. All efficacy analyses were per-
formed on the intent-to-treat (ITT) population. Survival
curves were estimated based on the Kaplan-Meier method.
Cox proportional hazards models, adjusted for the strati-
fication factors used at randomization, were fitted to the
data to obtain the HR and associated CIs. The proportional
hazards assumption was tested using the Grambsch-
Therneau test based on the ranks of the failure times,
using a significance level of P 5 .1 as a guide. Restricted
mean survival time (RMST) was emphasized in the pres-
ence of nonproportionality, using a time horizon (t*) of
10 years.17 The RMST is the area under the survival dis-
tribution from 0 to t* and is interpreted as the life expec-
tancy between randomization (t 5 0) and a particular time
horizon (t 5 tp).18 To estimate the survival distribution, we
fitted flexible parametric models with (3, 1) df and ad-
justed for the stratification factors and time to event. All
tests are presented as two sided, with 95% CIs and relevant
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P values. AE data are summarized for the safety population,
defined as participants who received at least one dose of
their allocated trial treatment.
RESULTS
Participants
We randomly assigned 1,711 participants from 147 sites in
seven countries between July 24, 2007, and April 12,
2013; 430 participants were assigned to placebo for 3 years
(arm A), 642 to sorafenib for 1 year followed by placebo for
2 years (arm B), and 639 to sorafenib for 3 years (arm C).
The number of participants who did not receive any drug or
placebo were five, 17, and 26 patients in arms A, B, and C,
respectively; these participants are included in the ITT
analysis for primary efficacy but excluded from the safety
analysis (Fig 1). Median follow-up at the time of analysis
was 6.5 years (interquartile range [IQR], 4.9-8.0 years). The
baseline characteristics of participants are listed in Table 1
and were well balanced across the treatment arms.
DFS
We observed no difference in DFS between patients ran-
domly assigned to 3 years of sorafenib and those assigned
to placebo (HR, 1.01; 95% CI, 0.82 to 1.23; P5 .946; 245
events for 3 years of sorafenib and 167 events for placebo).
We observed nonproportional hazards (P 5 .042); the
RMST estimate over 10 years was 6.81 years (95% CI, 6.52
to 7.11 years) for 3 years of sorafenib and 6.82 years
(95% CI, 6.45 to 7.18 years) for placebo (difference, 0.01
year; P 5 .988).
Patients randomly assigned to the trial
(N = 1,711)
 3 years of placebo
(n = 430)
Started treatment
Reasons for not starting
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FIG 1. CONSORT di-
agram. DFS, disease-
free survival; OS, overall
survival.
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TABLE 1. Baseline Characteristics
Characteristic
3 Years of Placebo
(n 5 430)
1 Year of Sorafenib Plus 2 Years of
Placebo (n 5 642)




Mean age at random assignment, years (SD) 58.43 (10.35) 58.34 (10.60) 57. 97 (10.86) 58.22 (10.63)
Time from RCC diagnosis to random assignment, days
(SD)
84.03 (26.33) 82.24 (31.86) 83.23 (30.65) 83.06 (30.09)
Country
Australia 42 (10) 62 (10) 64 (10) 168 (10)
Belgium 11 (3) 12 (2) 13 (2) 36 (2)
Denmark 5 (1) 8 (1) 7 (1) 20 (1)
France 32 (7) 45 (7) 45 (7) 122 (7)
The Netherlands 5 (1) 8 (1) 6 (1) 19 (1)
Spain 4 (1) 6 (1) 5 (1) 15 (1)
United Kingdom 331 (77) 501 (78) 499 (78) 1,331 (78)
Sex
Female 124 (29) 190 (30) 181 (28) 495 (29)
Male 306 (71) 452 (70) 458 (72) 1,216 (71)
WHO status
0 345 (80) 517 (81) 501 (78) 1,363 (80)
1 83 (19) 121 (19) 131 (21) 335 (20)
2 — — 1 (0) 1 (0)
Missing 2 (0) 4 (1) 6 (1) 12 (1)
Histology
Clear cell 361 (84) 534 (83) 550 (86) 1,445 (84)
Papillary 33 (8) 58 (9) 37 (6) 128 (7)
Chromophobe 29 (7) 31 (5) 36 (6) 96 (6)
Collecting duct 1 (0) 2 (0) 1 (0) 4 (0)
Other 6 (1) 17 (3) 15 (2) 38 (2)
Pathologic T stage of primary tumor
pT1a 3 (1) 2 (0) 2 (0) 7 (0)
pT1b 44 (10) 82 (13) 71 (11) 197 (12)
pT2 103 (24) 154 (24) 143 (22) 400 (23)
pT3a-4 280 (65) 404 (63) 423 (66) 1,107 (65)
Regional lymph node status
pNx/pN0 412 (96) 619 (96) 606 (95) 1,637 (96)
pN1/pN2 18 (4) 23 (4) 33 (5) 74 (4)
Tumor size, cm
, 10 286 (67) 436 (68) 430 (67) 1,152 (67)
. 10 144 (33) 206 (32) 209 (33) 559 (33)
Nuclear grade
1 19 (4) 38 (6) 32 (5) 89 (5)
2 105 (24) 159 (25) 176 (28) 440 (26)
3 222 (52) 323 (50) 314 (49) 859 (50)
4 84 (20) 122 (19) 116 (18) 322 (19)
Missing — — 1 (0) 1 (0)
(continued on following page)
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Comparing 1 year of sorafenib versus placebo, we also
observed no difference in DFS (HR, 0.94; 95% CI, 0.77 to
1.14; P5 .509; 245 events for 1 year of sorafenib and 167
events for placebo). Again, nonproportional hazards were
evident (P 5 .001). The RMST estimate over 10 years was
6.98 years (95% CI, 6.70 to 7.27 years) for 1 year of
sorafenib and 6.79 years (95% CI, 6.43 to 7.16 years) for
placebo (difference, 0.19 year; P 5 .422).
TABLE 1. Baseline Characteristics (continued)
Characteristic
3 Years of Placebo
(n 5 430)
1 Year of Sorafenib Plus 2 Years of
Placebo (n 5 642)





No 192 (45) 284 (44) 298 (47) 774 (45)
Yes 238 (55) 358 (56) 341 (53) 937 (55)
Leibovich score
3 30 (7) 65 (10) 56 (9) 151 (9)
4 83 (19) 129 (20) 135 (21) 347 (20)
5 111 (26) 148 (23) 153 (24) 412 (24)
6 99 (23) 139 (22) 131 (21) 369 (22)
7 48 (11) 73 (11) 80 (13) 201 (12)
8 30 (7) 53 (8) 48 (8) 131 (8)
9 24 (6) 32 (5) 26 (4) 82 (5)
10 3 (1) 1 (0) 4 (1) 8 (0)
11 2 (0) 2 (0) 6 (1) 10 (1)
Leibovich score group
Intermediate 224 (52) 342 (53) 344 (54) 910 (53)
High 206 (48) 300 (47) 295 (46) 801 (47)
NOTE. Data presented as No. (%), unless otherwise indicated.
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FIG 2. Disease-free sur-
vival in patients randomly
assigned to (A) 3 years
of sorafenib versus pla-
cebo and (B) 1 year of
sorafenib versus placebo.
Journal of Clinical Oncology 4069
SORCE: Adjuvant Sorafenib for Renal Cell Carcinoma
Downloaded from ascopubs.org by CAMBRIDGE University MEDICAL LIBRARY on March 22, 2021 from 131.111.184.102
Copyright © 2021 American Society of Clinical Oncology. All rights reserved. 
Median DFS was not reached in any of the arms in SORCE.
Ten-year DFS rate was 54% for placebo, 53% for 3 years of
sorafenib and 55% for 1 year of sorafenib (Fig 2).
OS
At the time of analysis, 371 patients had died; the causes of
death are listed in Table 2 and Appendix Table A2 (online
only). No difference in duration of OS was observed (3 years
of sorafenib v placebo: HR, 1.06; 95% CI, 0.82 to 1.38;
P5 .638; 1 year of sorafenib v placebo: HR, 0.92; 95% CI,
0.71 to 1.20; P5 .541). Proportional hazards were observed,
so as per our statistical analysis plan, we have not reported
RMST. Ten-year OS rate was 69% for placebo, 70% for
3 years of sorafenib, and 69% for 1 year of sorafenib (Fig 3).
Preplanned DFS Subgroup Analyses
We observed no difference in DFS for either 3 years or
1 year of sorafenib compared with placebo in our two
preplanned and prepowered analyses in participants with
Leibovich high-risk disease and in those with clear cell RCC
or in our modified DFS population (Appendix Tables A3 and
A4 and Figs A1 and A2, online only).
AEs and Safety
In total, 1,663 (97%) of 1,711 patients started treatment
and are included in the safety analysis (placebo, n 5 425;
1 year of sorafenib, n 5 625; and 3 years of sorafenib,
n5 613). Almost all patients in the safety population had at
least one AE of any grade (99%). At least one grade $ 3
AE was reported by 366 patients (58.6%) receiving 1 year
of sorafenib, 392 patients (63.9%) receiving 3 years of
sorafenib, and 124 patients (29.2%) receiving placebo.
The proportion of patients who experienced at least one
serious AE (SAE) was 19.1% for placebo, 21.6% for 1 year
of sorafenib, and 24% for 3 years of sorafenib. Table 3
TABLE 2. Cause of Death by Treatment Arm
Cause of Death
No. of Patients
Placebo 1 Year of Sorafenib 3 Years of Sorafenib
Disease related 77 105 122
Protocol treatment related 0 1a 0
Other cause 17 25 20
Missing 2 1 1
Total 96 132 143
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FIG 3. Overall survival in
patients randomly assigned
to (A) 3 years of sorafenib
versus placebo and (B)
1 year of sorafenib versus
placebo. The figures have
been truncated at 11 years.
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provides a breakdown of AEs and SAEs by arm. Worst grade
of AEs reported in each of the three arms is also listed in
Table 3. Notable toxicities were hand-foot skin reactions
and hypertension.
Other Secondary Outcome Measures
Results from the analyses of both MFS and RCC-specific
survival time are provided in the Appendix (Appendix
Tables A5 and A6 and Figs A3 and A4, online only). Results
from the TRANSORCE studies completed to date and our
patient and clinician preferences for adjuvant sorafenib
substudies are reported separately.19,20
Dose Delivered and Duration of Therapy
Two hundred twenty-six participants (13%) started treat-
ment on the full dose of 400 mg twice daily; the remaining
TABLE 3. Patients in the Safety Population Who Experienced AEs and Serious AEs and the Worst Grade AE Reported
AE Placebo 1 Year of Sorafenib 3 Years of Sorafenib
Any grade AE (at least one), No. (%) 414 (97.4) 625 (100) 608 (99.2)
Grade $ 3 AE (at least one), No. (%) 124 (29.2) 366 (58.6) 392 (63.9)
At least one serious AE 81 (19.1) 135 (21.6) 147 (24)
Adverse event, %a
Rash
Any grade 30 70 71
Grade 3 0 7 10
Grade 4 0 0 0
Diarrhea
Any grade 32 61 64
Grade 3 1 6 6
Grade 4 0 0 0
Hand-foot syndrome
Any grade 32 79 77
Grade 3 0 24 24
Grade 4 0 0 0
Fatigue
Any grade 60 74 74
Grade 3 2 4 4
Grade 4 0 0 0
Nausea
Any grade 26 34 30
Grade 3 1 1 0
Grade 4 0 0 0
Hypertension
Any grade 48 60 64
Grade 3 20 26 24
Grade 4 0 0 0
Alopecia
Any grade 12 54 49
Grade 3 0 0 0
Grade 4 0 0 0
Other
Any grade 87 88 89
Grade 3 9 12 17
Grade 4 1 1 2
Abbreviation: AE, adverse event.
aPercentages are based on the number of patients in the safety population in each arm.
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participants (n 5 1,485, 87%) started treatment on an
initial dose of 400 mg once daily for the first 3 weeks, which
could be extended for longer if required. Dose reductions in
the event of significant toxicity and subsequent re-
escalation on resolution were permitted. As in the other
adjuvant TKI trials in patients with RCC and despite the
permitted dose modifications, many participants did not
complete their assigned protocol treatment, even in the
placebo arm. Approximately half of participants had
withdrawn from treatment by the end of the first year in both
treatment arms (Appendix Table A7, online only). We
present time to discontinuation or termination of treatment
in Appendix Figure A5 (online only). Appendix Figure A6
(online only) presents months on treatment against total pill
count for each treatment arm, graphically illustrating that
patients found it difficult to comply with protocol treatment
and many patients ended treatment prematurely.
Median number of months on treatment was 35.4 months
(IQR, 11.4-35.9 months) for placebo, 11.7 months (IQR,
1.9-35.6 months) for 1 year of sorafenib, and 10.6 months
(IQR, 2.3-35.2 months) for 3 years of sorafenib. The re-
duced starting dose, although introduced quite early on in
the trial, had little overall effect on the median (or mean)
number of months on treatment (Appendix Table A8, online
only). Reasons for stopping treatment are listed in Table 4.
Treatment on Recurrence
The number of participants in each arm who received
additional systemic treatment after progression was similar
in each of the arms (Appendix Table A9, online only).
DISCUSSION
SORCE was an international, phase III trial investigating
sorafenib, an oral multikinase inhibitor, in patients with
resected RCC at intermediate or high risk of recurrence and
including all histologic subtypes. We observed no differ-
ence in DFS for either 3 years or 1 year of sorafenib
compared with placebo in the overall trial population, the
Leibovich high-risk participants, or participants with clear
cell RCC. Similarly, we showed no difference in duration of
OS between participants who received 3 years or 1 year of
sorafenib versus placebo. We did not observe proportional
hazards; we found an apparent separation between the
curves, but it does not support further investigation when
the overall results are so definitive.
Our results are in line with those from the ASSURE trial,
which showed no benefit of 1 year of sunitinib or sorafenib
compared with placebo (DFS: HR, 1.02 [97.5% CI, 0.85 to
1.23] and 0.97 [97.5% CI, 0.80 to 1.17] for sunitinib and
sorafenib, respectively).8 They are also in line with the
PROTECT and ATLAS trial results.7,9 S-TRAC was the only
study to show a modest DFS benefit with 1 year of sunitinib
(HR, 0.76; 95% CI, 0.59 to 0.98; P 5 .03) but only when
DFS events were subject to blinded independent central
review; no improvement in OS was observed.10,11 Appendix
Table A10 (online only) summarizes the inclusion criteria
and risk scores used in these trials.
Drug toxicity and the resultant reticence of participants to
stay on treatment were observed in all of the adjuvant TKI
trials; SORCE was no different. We amended the SORCE
protocol after , 18 months of accrual. The TMG had
noticed that many patients were stopping treatment as
a result of toxicity (particularly skin rash). Our IDMC en-
couraged an amendment when they reviewed the un-
blinded data in October 2008. We submitted an amended
protocol for ethics and regulatory approval in November
2008, and the change was implemented at sites in
January 2009.
Despite reducing the initial dose for the first 3 weeks,
allowing flexibility in the requirement for escalation to full
standard dose, and encouraging dose reductions to miti-
gate toxicity, only 33% and 25% of SORCE participants
completed 1 and 3 years of protocol treatment, re-
spectively. Approximately half of participants had with-
drawn from treatment by the end of the first year in both
treatment arms, with excessive toxicity and patient refusal
cited as the dominant reasons for stopping. In SORCE,
TABLE 4. Reasons Patients Stopped Treatment in the SORCE Trial
Reason for Stopping Treatment
% of Patients
Placebo 1 Year of Sorafenib 3 Years of Sorafenib
Protocol treatment completed 55 33 25
Disease progression 24 15 13
Excessive toxicity 4 30 34
Patient refusal 8 14 15
Clinical decision/other medical condition 3 6 9
New primary cancer 1 1 1
Death 0.2 0.3 0.2
Other (error/administrative reasons) 1 1 2
Missing 2 1 1
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grade $ 3 AEs were reported in 59%-64% of participants
on treatment, which is comparable to findings in other TKI
trials. Hand-foot skin reaction and hypertension caused the
most grade 3 events in the 1- and 3-year cohorts, which we
were unable to mitigate with our dosing strategy. Ultimately,
the high AE rates leading to dose reductions and early
stoppages, seen across all adjuvant TKI trials, are likely to
have affected the efficacy of TKIs in this setting. An ex-
ploratory analysis conducted as part of a systematic review
and pooled analysis of trial data from SORCE, ASSURE, and
PROTECT suggests that participants who started on full
dose may have an improved DFS (HRrandom, 0.83; 95% CI,
0.73 to 0.95; P 5 .005).13 However, this is exactly the
limiting factor because full-dose treatment was only
achieved in aminority of participants who took part in any of
the VEGF-targeted adjuvant trials.
The risk-benefit profile of additional treatment is an es-
sential consideration in patients receiving treatment and
experiencing toxicity in the adjuvant setting without overt
metastatic disease. The significant toxicity observed with
TKI monotherapy, despite pragmatic dose reductions, to-
gether with lack of evidence of a survival benefit, funda-
mentally undermines the use of TKIs in the adjuvant
treatment of RCC. The results from our patient preferences
for an adjuvant sorafenib substudy support this observa-
tion. Treatment duration and the toxicity patients experi-
enced were both important determinants of patients’
preferences for adjuvant sorafenib. A typical participant
who had been treated with adjuvant sorafenib judged that
to warrant continuing it for 3 years, a median survival gain of
an additional 9-12 months would be required, above and
beyond the 9-12 months required to make the initial 1 year
of adjuvant therapy worthwhile.21
In SORCE, imaging alternated between chest x-ray and
contrast CT of the chest and abdomen every 3 months
during treatment. After completion of treatment, partici-
pants had chest x-rays only every 6 months until year 5 and
then annually until year 10, but with advice to confirm
clinical signs of recurrence via CT or x-ray or a positive
biopsy. This was different from the other TKI trials, which
used CT scans or magnetic resonance imaging throughout.
Of our 654 disease recurrence events, 547 were reported
on CT scan, only nine were reported on chest x-ray, and 77
were reported using mixed modalities or biopsies (in-
formation is missing for 21 participants). Method of as-
sessment was similar across arms.
Effective adjuvant therapy for patients who have had their
primary renal cancer removed by surgery remains an
unmet clinical need. The international infrastructure de-
veloped to conduct SORCE over the years has paved the
way for our current adjuvant trial RAMPART (Clinical-
Trials.gov identifier: NCT03288532), a University College
London–sponsored multiarm, multistage platform trial in-
vestigating single-agent durvalumab (anti–programmed
death ligand-1) and durvalumab in combination with
tremelimumab (anti–cytotoxic T-lymphocyte–associated
protein 4). Numerous other adjuvant trials investigating
immune checkpoint inhibitors either as monotherapies or
in combination are ongoing and will report over the
coming years.
The results from SORCE unequivocally confirm that sor-
afenib should not be used as adjuvant therapy for patients
with resected RCC at intermediate or high risk of relapse.
We observed no DFS or OS benefit for up to 3 years of
sorafenib treatment in this patient group, yet participants
experienced a range of treatment-associated toxicities.
Active surveillance remains the global standard of care for
patients at intermediate or high risk of recurrence after
nephrectomy and is the appropriate control arm of our
current international adjuvant RCC trial, RAMPART.
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APPENDIX
Subgroup Analyses
Power to analyze whether up to 3 years of sorafenib increases
disease-free survival compared with placebo was calculated based
on event rates estimated from published data (STRAC, ASSURE,
and ATLAS). With 506 participants with a high-risk Leibovich score
in arms A and C and assuming an event rate of 53%, we had 65%
power to detect a hazard ratio (HR) of 0.75 at the 5% two-sided
significance level. Similarly, with 898 participants with clear cell
histology in arms A and C and assuming an event rate of 47%, we
had 84% power to detect an HR of 0.75 at the 5% two-sided
significance level.
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FIG A1. Kaplan-Meier curves of the prespecified and prepowered disease-free survival analyses in Leibovich
high-risk patients.
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FIG A2. Kaplan-Meier curves of the prespecified and prepowered disease-free survival analyses in patients with
clear cell renal cell carcinoma.
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FIG A3. Kaplan-Meier curves for metastasis-free survival.
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FIG A4. Kaplan-Meier curves for renal cell carcinoma (RCC)–specific survival.
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FIG A5. Time to discontinuation or end of treatment by arm, (A) overall and by starting dose: (B) full dose and (C)
reduced dose.
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FIG A6. Months on treatment versus total pill count taken per participant in each of the arms. For patients who
reached 36 months on treatment, total pill count varied significantly.
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TABLE A2. Summary of Other Causes of Death by Treatment Arm
Cause
No. of Patients
Placebo 1 Year of Sorafenib 3 Years of Sorafenib
Cardiovascular 2 5 3
Drug reaction (not trial drug) 1 0 0
Infection 3 6 4
Neurologic disease 0 0 1
Other malignancy 4 9 2
Respiratory 2 0 3
Surgical complication 0 0 1
Trauma 0 0 1
Unknown 5 4 5
Total 17 24 20
TABLE A1. Leibovich Risk Score Components and Risk Group
Categories
Feature Score





Regional lymph node status












NOTE. Leibovich score is the sum of the score given for each feature:
low risk, score of 0-2; intermediate risk, score of 3-5; and high risk,
score of $ 6.
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TABLE A3. Summary of DFS Results in Leibovich High-Risk Patients, in Patients With Clear Cell RCC, and in the Modified DFS Population
Comparison
DFS RMST
HR (95% CI) P




Leibovich high risk, 3 years of sorafenib (n5 295) v placebo v
(n 5 206)
1.02 (0.80 to 1.30) .875 5.37 (4.89 to 5.85) v
5.44 (4.85 to 6.03)
20.07 .86
Leibovich high risk, 1 year of sorafenib (n 5 300) v placebo
(n 5 206)
0.92 (0.72 to 1.17) .49 5.69 (5.23to 6.16) v
5.43 (4.85 to 6.01)
0.26 .50
Clear cell RCC, 3 years of sorafenib (n 5 550) v placebo
(n 5 361)
0.99 (0.80 to 1.23) .93 6.83 (6.51 to 7.15) v 6.79
(6.40 to 7.19)
0.033 .90
Clear cell RCC, 1 year of sorafenib (n 5 534) v placebo
(n 5 361)
0.94 (0.75 to 1.16) .55 7.01 (6.7 to 7.32) v
6.82 (6.42 to 7.22)
0.19 .46
NOTE. In Leibovich high-risk patients, we observed no difference in DFS between patients randomly assigned to 3 years of sorafenib versus placebo or to
1 year of sorafenib versus placebo; nonproportional hazards were observed (P 5 .01 and P , .0001, respectively). The RMST estimates over 10 years are
shown in the table. In patients with clear cell RCC, we also observed no difference in DFS between patients randomly assigned to 3 years of sorafenib versus
placebo or to 1 year of sorafenib versus placebo; nonproportional hazards were observed (P 5 .08 and P , .0001, respectively). The RMST estimates over
10 years are shown in the table.
Abbreviations: DFS, disease-free survival; HR, hazard ratio; RCC, renal cell carcinoma; RMST, restricted mean survival time.
TABLE A4. Summary of Modified DFS Results
Comparison
Modified DFS2 RMST
HR (95% CI) P




3 years of sorafenib (n5 639) v placebo (n5 430) 1.02 (0.85 to 1.23) .83 6.43 (6.13 to 6.84) v 6.47 (6.11 to 6.84) 0.045 .85
1 year of sorafenib (n 5 642) v placebo (n 5 430) 0.96 (0.80 to 1.15) .64 6.57 (6.27 to 6.86) v 6.44 (6.07 to 6.81) 0.13 .61
NOTE. The following modified definition of DFS was explored to align with the definition used in the ASSURE and S-TRAC trials: time from randomization to
first evidence of recurrence, development of any second primary cancer, or death from any cause.
Abbreviations: DFS, disease-free survival; HR, hazard ratio; RMST, restricted mean survival time.
TABLE A5. Metastasis-Free Survival Analysis
Comparison
Metastasis-Free Survival RMST
HR (95% CI) P




3 years of sorafenib (n5 639) v placebo (n5 430) 1.00 (0.82 to 1.22) .98 6.89 (6.60 to 7.19) v 6.88 (6.52 to 7.24) 0.01 .97
1 year of sorafenib (n 5 642) v placebo (n 5 430) 0.90 (0.74 to 1.10) .31 7.13 (6.84 to 7.41) v 6.86 (6.50 to 7.23) 0.27 .27
Abbreviations: HR, hazard ratio; RMST, restricted mean survival time.





HR (95% CI) P




3 years of sorafenib (n5 639) v placebo (n5 430) 1.12 (0.85 to 1.50) .42 8.57 (8.35 to 8.79) v 8.71 (8.45 to 8.96) 20.14 .42
1 year of sorafenib (n 5 642) v placebo (n 5 430) 0.91 (0.68 to 1.22) .52 8.81 (8.61 to 9.02) v 8.68 (8.42 to 8.94) 0.13 .44
Abbreviations: HR, hazard ratio; RMST, restricted mean survival time.
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TABLE A7. Time on Trial Before Stopping Treatment
Months on Treatment
No. of Patients (%)
Placebo 1 Year of Sorafenib Plus 2 Years of Placebo 3 Years of Sorafenib
# 1 11 (3) 98 (15) 88 (14)
1-2 8 (2) 58 (9) 55 (9)
2-3 5 (1) 31 (5) 25 (4)
3-6 43 (10) 71 (11) 76 (12)
6-12 43 (10) 59 (9) 74 (12)
12-18 20 (5) 37 (6) 49 (8)
18-24 19 (4) 25 (4) 39 (6)
24-30 20 (5) 24 (4) 29 (5)
30-361 244 (57) 218 (34) 178 (28)
NOTE. Percentages are based on the number of randomly assigned patients in each arm.
TABLE A8. Time on Treatment
Measure Placebo 1 Year of Sorafenib 3 Years of Sorafenib
Overall
Median time on treatment, months (IQR) 35.42 (11.43-35.94) 11.19 (2.00-12.16) 10. 71 (2.27-35.29)
Mean time on treatment, months (SD) 25.63 (13.24) 7.78 (5.21) 16.08 (14.35)
Full dose
No. of patients 57 84 85
Median time on treatment, months (IQR) 31.41 (6.72-35.86) 5.98 (1.12-12.19) 12.58 (2.20-35.65)
Mean time on treatment, months (SD) 23.31 (14.04) 7.20 (5.56) 17.69 (14.54)
Reduced dose
No. of patients 373 558 554
Median time on treatment, months (IQR) 35.48 (12.22-35.98) 11.27 (2.30-12.16) 10.15 (2.33-35.19)
Mean time on treatment, months (SD) 25.99 (13.10) 7.86 (5.15) 15.82 (14.32)
Abbreviations: IQR, interquartile range; SD, standard deviation.
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TABLE A9. Summary of First Posttrial Treatment
Treatment
No. of Patients (%)
Placebo 1 Year of Sorafenib Plus 2 Years of Placebo 3 Years of Sorafenib Total
Sunitinib 34 (8) 54 (8) 64 (10) 152 (9)
Pazopanib 19 (4) 40 (6) 45 (7) 104 (6)
Sorafenib 14 (3) 8 (1) 2 (0.3) 24 (1)
Interferon-a, interleukin-2, fluorouracil 3 (1) 6 (1) 3 (0.5) 12 (0.7)
Other 12 (3) 19 (3) 16 (3) 47 (3)
Total 82 (20) 127 (20) 130 (20) 339 (20)
NOTE. Percentages are based on the number of randomly assigned patients in each arm.
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TABLE A10. Characteristics, Inclusion Criteria, and Risk Scores of Completed Adjuvant Trials for Kidney Cancer
Characteristic
ASSURE (ClinicalTrials.gov
identifier: NCT00326898) S-TRAC PROTECT ATLAS SORCE
No. of patients 1,943 615 1,538 724 1,711
Treatment arms Sunitinib or sorafenib v
placebo
Sunitinib v placebo Pazopanib v
placebo
Axitinib v placebo Sorafenib for 1 year or





1 1 1 3 3
Inclusion criteria TNM 2002 staging:
pT1b, G3-4, N0 or pNx, M0
pT2, G any, N0 or pNx, M0
pT3, G any, N0 or pNx, M0
pT4, G any, N0 or pNx, M0
pT any, G any, N1 (fully
resected), M0
TNM 2002 staging:
pT2, G3-4, N0 or pNx,
M0
pT3, G any, N0 or pNx,
M0
pT4, G any, N0 or pNx,
M0




pT2, G3-4, N0 or
pNx, M0
pT3, G any, N0 or
pNx, M0
pT4, G any, N0 or
pNx, M0
pT any, G any, N1,
M0
TNM 2010 staging:
pT2, G any, pN0 or pNx,
M0
pT3, G any, pN0 or pNx,
M0
pT4, G any, pN0 or pNx,
M0
Any pT, G any, pN1, M0
TNM 2002 staging:
pT any, N1-2, M0 as per
Leibovich score of 3-11

















M0 patients with evidence
of microscopic disease
(R1) are acceptable
Histology Clear cell and non–clear cell Clear cell predominant Clear cell
predominant
(. 50%)
Clear cell predominant (.
50%)




ECOG 0-1 ECOG 0-2 Karnofsky
performance
score $ 80
ECOG 0-1 ECOG 0-1
Risk score Modified UISS intermediate
high to very high
Modified UISS high risk SSIGN
intermediate to
high risk
TNM and Fuhrman grade Leibovich intermediate to
high
Abbreviations: ECOG, Eastern Cooperative Oncology Group; SSIGN, stage, size, grade and necrosis; UISS, University of California Los Angeles Integrated
Staging System.
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